Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

"As an aside, the Ross procedure, which is my preference in this age group, is the only aortic valve replacement procedure ...

LOS ANGELES -- Cardiac surgeons were urged to readjust their attitudes toward the tricuspid valve if they want to keep some ...

CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...

GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...

Annual Meeting reveals that mechanical aortic valve replacements (AVRs) provide significant long-term survival benefits for ...

SGMC Health recently achieved the successful completion of its first transcarotid access Transcatheter Aortic Valve ...

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...

The US Food and Drugs Administration (FDA) is expected to approve the JenaValve Trilogy System, a transcatheter aortic valve ...

The Navitor Vision, Abbott's latest TAVI system, is designed to improve accuracy during implantation and enhance visibility ...

Abbott introduces Navitor Vision in India, the next generation of heart valve technology designed to treat aortic stenosis: Our Bureau, Mumbai Thursday, January 30, 2025, 15:15 Hr ...

Navitor Vision enhances visibility and precision in TAVI procedures, offering a less invasive alternative to surgical aortic ...